Osteoporosis is a common skeletal disorder characterized by low bone mass leading to increased bone fragility and fracture susceptibility. In this study, we have identified pathways that stimulate differentiation of bone forming osteoblasts from human mesenchymal stromal cells (hMSCs). Gene expression profiling was performed in hMSCs differentiated toward osteoblasts (at 6 h). Significantly regulated genes were analyzed in silico, and the Connectivity Map (CMap) was used to identify candidate bone stimulatory compounds. The signature of parbendazole matches the expression changes observed for osteogenic hMSCs. Parbendazole stimulates osteoblast differentiation as indicated by increased alkaline phosphatase activity, mineralization, and up-regulation of bone marker genes (alkaline phosphatase/ALPL, osteopontin/SPP1, and bone sialoprotein II/IBSP) in a subset of the hMSC population resistant to the apoptotic effects of parbendazole. These osteogenic effects are independent of glucocorticoids because parbendazole does not up-regulate glucocorticoid receptor (GR) target genes and is not inhibited by the GR antagonist mifepristone. Parbendazole causes profound cytoskeletal changes including degradation of microtubules and increased focal adhesions. Stabilization of microtubules by pretreatment with Taxol inhibits osteoblast differentiation. Parbendazole up-regulates bone morphogenetic protein 2 (BMP-2) gene expression and activity. Cotreatment with the BMP-2 antagonist DMH1 limits, but does not block, parbendazole-induced mineralization. Using the CMap we have identified a previously unidentified lineage-specific, bone anabolic compound, parbendazole, which induces osteogenic differentiation through a combination of cytoskeletal changes and increased BMP-2 activity.
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Connectivity Map | osteoblast | mesenchymal stem cell | cytoskeleton | osteoporosis O steoporosis is a common and devastating bone disease characterized by reduced bone mass and increased fragility and fracture risk. It has been estimated that an osteoporotic fracture occurs once every 8 s worldwide (1) , and direct healthcare costs in Europe alone are at least V31.7 billion annually (2) . Osteoporosis means porous bones and occurs when bone remodeling is disrupted. Bone remodeling is a balancing act between removal of old bone and formation of new bone, which is achieved by two distinct cells, the osteoclast and osteoblast, respectively. When uncoupling of these two processes takes place, bone resorption can overtake bone formation, resulting in osteoporosis. Most osteoporosis treatments, such as bisphosphonates, reduce bone resorption and result in modest increases in bone density; however, these treatments do not result in a true bone anabolic effect, so patients do not regain bone that has been lost at time of diagnosis. An ideal treatment would stimulate bone formation as well, to help repair the damage already done to the bone microarchitecture and strength; with this in mind, our goal was to search for previously unidentified molecules and/or mechanisms that stimulate human osteoblast differentiation and bone formation.
The connectivity map (CMap) is a web-based tool that allows for screening of compounds against a genome-wide disease or physiological gene signature (3, 4) . This screening is achieved by comparing microarray data from more than 1,300 small molecules to a user's selected gene signature of the phenotype of interest using a pattern-matching algorithm with a high level of resolution and specificity. The screening results in a list of compounds with a highly correlating gene expression pattern to that of the phenotype of interest, which has the potential to aid in finding a novel treatment for a disease or to identify novel pathways or genes involved in a complex biological process. To date, the CMap has been successfully used to identify compounds and combination therapies that show promise in the treatment of osteoarthritic pain (5), adenocarcinoma (6), kidney disease (7), gliomas (8) , and NK cell neoplasms (9) .
Our aim was to identify previously unidentified anabolic therapeutic targets by genomic, proteomic, and bioinformatic dissection of human mesenchymal stromal cell (hMSC)-derived osteoblasts. Therefore, we used the CMap to identify compounds with a matching gene expression profile to human mesenchymal stem cells undergoing osteogenic differentiation. By following this approach, we aimed to not only discover novel compounds that stimulate osteogenic differentiation, but also novel processes underlying this process.
Results
Parbendazole Has the Strongest Correlating Gene Signature to hMSCs Undergoing Osteoblast Differentiation. Using a pattern-matching algorithm, the CMap links compounds with disease or physiological phenotypes by measuring similarities in gene expression (3) . To identify compounds that may exert bone anabolic effects due to their ability to stimulate genes regulated during osteoblast Significance Osteoporosis, a disease characterized by increased bone fragility and fracture risk, affects over 20% of the ever-growing elderly population. It is important to further our knowledge of bone cell biology so we can develop new bone anabolic treatments. By combining genomic and bioinformatic tools against the backdrop of osteogenic differentiating human mesenchymal stromal cells, we have identified a previously unidentified bone anabolic compound that induces osteoblast differentiation in a subset of the hMSC population through cytoskeletal changes and increased bone morphogenetic protein 2 activity. Through this novel approach we identified an important mechanism of lineage allocation and demonstrated the significance of cytoskeletal organization in osteogenic differentiation, providing us with a novel mechanism for bone formation to target for new osteoporosis treatments.
differentiation, we performed a CMap analysis in which we searched for drugs that have a gene expression pattern positively correlating to hMSCs differentiating toward osteoblasts (Table S1 ). Multiple drugs were identified that have a significantly correlating gene expression pattern to that of differentiating human osteoblasts, including dexamethasone (dex) and a number of other corticosteroids (Table 1 ). These results demonstrate the validity of the CMap, because dex is the compound that we originally used to stimulate osteoblast differentiation and glucocorticoid (GC)-mediated activation of the glucocorticoid receptor (GR) is the classical stimulus for human osteoblast differentiation. Because our aim was to identify novel compounds/pathways that stimulate osteoblast differentiation, we excluded any corticosteroid compound for further testing. We found that the strongest correlating compound (P < 0.0001) ( Table 1) , and only noncorticosteroid in the top eight compounds, is the benzimidazole anthelmintic parbendazole. Based on these results, we chose to scrutinize the effects parbendazole has on hMSCs in regard to its osteogenic potential.
Parbendazole Induces Osteoblast Differentiation of hMSCs in Vitro.
Similar to the known stimulator of osteogenic differentiation, dex, parbendazole treatment stimulated alkaline phosphatase (ALP) activity after 1 wk of culture and mineralization after 3 wk of culture, dose dependently up to 4 μM ( Fig. 1 A and B , respectively). We confirmed the dose-dependent parbendazoleinduced mineralization by alizarin red staining (Fig. 1C) . These results show that parbendazole induces biochemical changes in hMSCs leading to osteoblast differentiation and mineralization.
We also examined if the most effective dose of parbendazole, 4 μM, induces expression of well-known osteoblast marker genes by performing quantitative PCRs on hMSCs treated with parbendazole for 7 d. Parbendazole significantly increased the expression of alkaline phosphatase (ALPL) (Fig. 1D) as well as the genes encoding the matrix proteins bone sialoprotein (IBSP) and osteopontin (SPP1) ( Fig. 1 E and F) .
Simian virus-immortalized human fetal osteoblasts (SV-HFO) treated with parbendazole did not mineralize (Fig. S1A ), and total protein was decreased by parbendazole ( Fig. S1B) at the doses stimulating osteogenesis in the hMSCs.
Taken together, these results demonstrate that parbendazole induces osteogenic differentiation of hMSCs independent of the known osteogenic stimulus, dexamethasone.
Parbendazole Increases Both Apoptosis and Proliferation. To determine how parbendazole may affect hMSC viability, we used FACS analysis to look at apoptosis and proliferation. Parbendazole increased apoptosis at day 5 and 8 of culture compared with control-treated hMSCs (44.8-58.5 vs. 15.8-17.9%, respectively; Fig.  2A ). We also found that at days 5 and 8 of culture, parbendazole significantly increased proliferation compared with controltreatment (24.7-26.1 vs. 9.1-10.4% Ki67+, respectively; Fig. 2B ). To verify the overall viability of hMSCs treated with parbendazole, we performed a PrestoBlue assay, a metabolism-based assay as a readout for cell viability. Parbendazole treatment led to a decrease in cell viability compared with both controls and dextreated hMSCs starting at day 4 of culture ( Fig. 2C ). These findings reveal that parbendazole is capable of increasing both proliferation and apoptosis in hMSCs, and because apoptosis (i.e., increased cell death and decreased cell survival) exceeds proliferation conditions, the total accumulation of cells is reduced in parbendazole-treated cells.
Parbendazole Induces Osteoblast Differentiation Independent of Glucocorticoid Receptor Signaling. To determine if parbendazole induces osteogenic differentiation through direct GR-mediated stimulation of osteoblast marker genes, similar to dex, we performed quantitative gene expression analyses for known GR target genes following parbendazole treatment. Dex-induced osteoblast differentiation strongly up-regulated the GR target genes ZNF145, GILZ, and FKBP51 (up to 10,000-fold), whereas parbendazole treatment did not ( Fig. 3 A-C), implicating that parbendazole acts independently of GR signaling. We then cultured dex-or parbendazole-treated hMSCs in combination with the GR antagonist mifepristone (RU486), which blocks signaling through the GR, and performed biochemical assays for osteoblast differentiation. Whereas mifepristone had no effect on induction of ALP activity (Fig. 3D ) or mineralization ( Top matching compounds from the Connectivity Map based on the average of the replicates of a single compound for each cell line. Shading indicates a glucocorticoid. Top matching compound and only nonglucocorticoid, parbendazole, in white. Rank is based on the P value calculated from the CMap scores all of the replicates of a single compound in a single cell line. Score is based on the relative strength of a given signature in an instance from the total set of instances calculated upon execution of a query. For PCRs, n = 6. *P < 0.05, **P < 0.01, ***P < 0.001. Results are presented relative to control.
parbendazole, it completely abolished dex-induc"ed increases in ALP activity (Fig. 3D ) and mineralization (Fig. 3E) . These results prove that parbendazole induces human osteoblast differentiation independent of GR signaling.
Parbendazole Inhibition of Microtubule Polymerization Is Required
for Parbendazole-Induced Osteogenic Differentiation. Parbendazole is known to be an inhibitor of microtubule formation (10), and we confirmed this in our hMSCs. In control (Fig. S2 A, D, and J) and dex-treated ( Fig. S2 C, F, and L) cultures, both the actin and microtubule structures are similarly distributed throughout the cell, whereas in parbendazole-treated hMSCs, the microtubule structure is severely degraded, leaving only short strands of microtubule filaments surrounding the nucleus (Fig. S2 E and K) . However, we observed numerous thick, crossing actin stress fibers present in cells treated with parbendazole ( Fig. S2B) , whereas in control-treated cells the actin filaments were primarily organized parallel to the cell axis (Fig. S2A ). To determine whether degradation of the microtubule structure is required for parbendazoleinduced osteogenic differentiation, we used the microtubule stabilizing agent paclitaxel (Taxol). Taxol completely abolished the parbendazole-induced mineralization of hMSCs (Fig. 4) . These results clearly demonstrate that inhibition of microtubule formation is required for parbendazole to elicit osteogenic differentiation of hMSCs.
Parbendazole Increases Focal Adhesions. Based on the evidence that cytoskeletal changes are induced by parbendazole during hMSC osteogenic differentiation, and previous evidence that cytoskeletal changes and integrin binding and signaling play a significant role in osteoblast differentiation (11-13), we investigated whether focal adhesions (FAs) are also affected by parbendazole. Analysis of immunofluorescent images show that FAs appear to be longer and more numerous following parbendazole treatment (Fig. S3 E, K, and N) compared with control treatment (Fig. S3  D, J, and M) . Quantification of the FAs revealed that parbendazole treatment significantly increased the number of focal adhesions compared with both control and dex treatment (Fig.  5A ) and increased their length compared with control ( Fig. 5B ) after 24 h of treatment.
Parbendazole Increases BMP-2 Expression and Activity. It has previously been demonstrated that microtubule inhibitors stimulate osteoblast differentiation and increase bone mass in mice through elevated levels of BMP-2 (14, 15) . We show that parbendazole significantly increased BMP2 expression (Fig. 6A) , whereas dex significantly inhibited BMP2 expression compared with controltreated cells. To determine BMP bioactivity stimulated by parbendazole, we used a C2C12-BRE-Luc reporter cell line (16, 17) . Incubation with conditioned media from hMSCs treated with parbendazole for 48 h significantly increased luciferase activity (Fig. 6B) , whereas conditioned medium from control and dex treatment had no effect. These results show that parbendazole stimulates BMP-2 signaling in hMSCs.
Inhibiting BMP-2 Signaling Limits Parbendazole-Induced Osteogenic hMSCs Differentiation. To determine whether BMP-2 is involved in the osteogenic effect of parbendazole, we used the BMP-specific antagonist DMH1 (18) . These studies demonstrated significant interaction between parbendazole and DMH1 resulting in limitation of osteogenic differentiation following the cotreatment of parbendazole and DMH1 compared with parbendazole or DMH1 alone (Fig. 6C) ; this reveals that BMP-2 signaling is involved in the effect of parbendazole on osteoblast differentiation of hMSC. In the control condition, DMH1 induced mineralization in hMSCs cultures, which is consistent with the results of Rifas (19) showing that inhibition of BMP signaling by another BMP antagonist, noggin, resulted in osteogenic differentiation of hMSCs.
Discussion
Using the CMap, we were able to identify a compound with a highly significant positively correlating gene expression profile to that of differentiating human osteoblasts. As expected, the top of the list of compounds was dominated by glucocorticoids, including dexamethasone; however, the top resulting compound was found to be parbendazole. We confirmed the validity and power of the CMap approach by demonstrating that parbendazole, independent of an additional osteogenic stimulus such as dexamethasone, is able to stimulate human osteoblast differentiation as evidenced by increased ALP activity, mineralization, and up-regulation of genes known to be important in osteoblast differentiation and function. Mechanistically, we showed that the osteogenic effect of parbendazole does not occur through glucocorticoid receptor signaling, but rather via affecting microtubule formation and cytoskeletal organization. Overall, our findings demonstrate that by using the CMap, we identified a novel compound that independently stimulates human osteogenic differentiation. The web-based resource CMap was created to identify compounds that induce a similar or opposite effect on the physiological processes or diseases of interest; as a consequence, it is a bioinformatics tool to identify novel applications for established drugs. The CMap uses several human tumor cell lines, including PC3, MCF7, and HL60, to generate gene expression profiles of more than 1,300 compounds. Interestingly, all of the top eight compound profiles most strongly correlating with our human osteoblast expression profile are derived from the PC3 cell line, a cell line originating from a bone metastasis of a prostate tumor (20) . An explanation for this intriguing observation is lacking, but it is tempting to hypothesize that, based on our CMap results, there must be a resemblance in the genomic profile of both osteogenic hMSCs and the bone metastatic PC3 cells, which is potentially linked to both of their abilities to thrive in the bone environment. A prerequisite of the CMap approach for discovering bone anabolic compounds is that one has to assume similarities in how different cell types respond to the same compound regarding gene expression. However, the evidence presented here, and the growing evidence from other groups (5-9), strongly supports the concept that CMap is a potent tool for identification of compounds with medicinal benefit for a wide range of diseases.
Benzimidazoles, including parbendazole, are a class of compounds that consist of the fusion of benzene and imidazole rings and are primarily used as anthelminthics (21) . The majority of these family members have a similar mechanism of action-namely, preventing tubulin polymerization through specific binding to tubulin (22, 23) . Parbendazole is no exception: it binds the tubulin dimer with a mol:mol stoichiometry and microtubules withdraw from the peripheral area of the cell within 30 min of treatment with parbendazole (10). Our immunocytological findings in osteogenic hMSC are consistent with the findings by Havercroft and coworkers. Disassembly of microtubules in other cell types has been associated with blebbing of the plasma membrane, indicative of apoptosis. Our FACS results showing that parbendazole treatment increases the number of annexin V positive cells in our cultures supports the idea that microtubule inhibition leads to increased apoptosis. However, Havercroft et al. (10) also showed that after 1 d of parbendazole treatment, cells flattened out without any signs of plasma membrane blebbing, despite absent microtubules. This morphology correlates to our observation that a subset of parbendazole-treated hMSCs displays a flattened, widespread morphology. Interestingly, although we do see an increase in apoptosis, we also observe an increase in the proliferation marker Ki67 at day 5 and 8 in hMSCs treated with parbendazole, which indicates that there are at least two populations of MSC in the bone marrow with different sensitivity to parbendazole. One population, likely the true stem cells, is resistant to the apoptotic effects of parbendazole and are induced to proliferate and eventually differentiate and mineralize, and another population, the precommitted cells, undergoes apoptosis. Taking the hMSC FACs data together with the biochemical results in the SV-HFOs, we propose that parbendazole acts at the stage of lineage allocation in hMSCs.
Microtubules are highly dynamic cytoskeletal elements that undergo continuous assembly and disassembly to maintain normal function (24, 25) ; they play an essential role in a variety of cellular processes, including mitosis, cell motility, and intra-and intercellular trafficking (26) , but are also taking part in various signaling pathways including those involving sonic hedgehog, Wnt, and MAPK (24, 27) . Microtubules act as binding sites for a number of proteins and transcription factors, including RUNX2; and in the case of RUNX2, modulate transcriptional activity by acting as a shuttle between the nucleus and cytoplasm (28) . It has been shown previously that Taxol treatment leads to depletion of nuclear levels of RUNX2 (28) , and this could also be one explanation for our results demonstrating that Taxol pretreatment blocks the osteogenic effect of parbendazole. Chang et al. (29) observed that short-term treatment of MSCs with a related compound, nocodazole, increased cell contractility and cytoskeletal tension followed by enhanced osteoblast differentiation. Cytoskeletal tension rises, and perhaps even directly stimulates, osteoblast differentiation through changes in the actin cytoskeleton (13, (30) (31) (32) (33) . In addition, disruption of the tubulin organization also affects the kinetics of actin organization (13), indicating a regulatory role for microtubules in actin reorganization. Cytoskeletal rearrangements may also affect osteoblast differentiation through enhanced integrin signaling. FA complexes and integrins are known to directly interact with extracellular matrix proteins, including SPP1 and IBSP, which play a critical role in osteoblast survival and differentiation (11, 30, 34, 35 ). An increased number of FAs is proposed to increase adhesion to the extracellular matrix (35, 36) , which may also contribute to osteogenic differentiation. The fact that parbendazole-treated hMSCs display a widespread, flattened morphology, prominent and rearranged actin fibers, increased focal adhesion complexes, and higher expression of SPP1 and IBSP, supports the idea that cytoskeletal rearrangements contribute to osteoblast differentiation through enhanced integrin signaling and/or matrix binding. Liu et al. (14) demonstrated a role for microtubule inhibitors as a bone anabolic drug by showing that stathmin, a ubiquitously expressed protein that inhibits microtubule assembly, promotes osteoblast differentiation and inhibits osteoclast activity; and mice lacking stathmin are osteopenic as a consequence of decreased osteoblast numbers and differentiation, and increased numbers of osteoclasts. Our results, demonstrating that changes in the balance between the tension forces of the microfilaments and the compression forces of the microtubules elicit changes in the cellular shape, function, and cell fate are in line with the cellular tensegrity model (37, 38) and with previous findings that changes in cell shape and cytoskeleton can strongly influence hMSC lineage decision-making (39) .
There is growing evidence that microtubule inhibitors have a positive effect on bone formation and osteoblast differentiation through increased BMP signaling. Zhao et al. (15) showed that several types of microtubule inhibitors, including nocodazole and TN16, increased Bmp2 expression and ALP activity in murine osteoblasts; additionally, the authors showed that short-term administration of TN16 locally over the calvaria or systemically in mice lead to increased calvarial periosteal bone formation and trabecular volume in long bones, respectively. It was shown in murine osteoblasts that the osteogenic effect of the inhibition of microtubule assembly is due to increased cytoplasmic Gli2 protein concentration through disassociation of the microtubule Gli-Ci complex that would otherwise lead to proteasomal degradation of Gli2 (15) . Gli2 enhances Bmp2 expression through BMP promoter binding (40) . Bmp-2 is known to be a potent stimulator of osteoblast differentiation in murine cells (41, 42; reviewed by 43), but the evidence for BMP-2 effects on human osteogenic differentiation in vitro is conflicting, ranging from strongly enhancing osteogenic differentiation (44, 45) to having no positive effect (46, 47) ; this may be, in part, due to differences in the BMP receptor expression profiles by the various osteoblast precursors and hMSC donors (44, 47) . Clinical trials looking at the efficacy of BMP-2 in fracture healing and fusions are mixed; two recent independent meta-analyses of human clinical trials comparing recombinant human BMP-2 to autologous bone grafts in spinal fusions found no significant difference in healing or pain (48, 49) . In this study we found that parbendazole treatment induces both BMP2 expression and BMP activity, as evidenced by our gene expression and reporter assay data; in support of this, the BMP inhibitor DMH1 (18) seems to limit the parbendazole-induced osteoblast mineralization in our hMSC cultures but does not completely block it. Thus, our data confirms a parbendazole-induced human osteogenic pathway through inhibition of microtubule assembly and increased BMP-2 activity.
In summary, we conclude that the CMap identified compound parbendazole is a novel compound that stimulates human osteoblast differentiation in vitro. We have proven that parbendazole, independent of additional osteogenic stimulus, stimulates ALP activity and mineralization, and up-regulates genes important in osteoblast differentiation and extracellular matrix production in a subset of hMSCs resistant to its apoptotic effects. In line with previous reports of other microtubule inhibitors, the stimulatory effect of parbendazole is partly due to increased BMP-2 activity; however, additional cytoskeletal-driven mechanisms, such as cytoskeletal-associated proteins and transcription factors, and integrin signaling, are likely to be of equal or greater importance in stimulating osteogenic differentiation of hMSCs. Though we do not propose parbendazole itself to be the ideal bone anabolic drug for treatment of osteoporosis in humans, the evidence presented here significantly strengthens the concept that cytoskeletal changes strongly influence hMSC lineage allocation and osteoblast differentiation. We envisage that cytoskeletal manipulation, or the downstream processes that results from it, hold promise as novel antiosteoporotic treatments, but this will need to be studied further. We have also clearly demonstrated the power of the CMap as an effective tool to discover bone anabolic compounds.
Materials and Methods
Further details of materials and methods are included in SI Materials and Methods and Table S2 .
Cell Culture. Human bone marrow-derived MSCs were cultured as described previously (50, 51) .
Connectivity Map Query. To find compounds that have similar gene expression patterns compared with our human osteogenic differentiation-induced gene expression patterns, we generated gene signatures from microarray gene expression analyses of bone marrow-derived hMSCs treated with dex to stimulate osteogenic differentiation. We identified the 100 most significantly (Z < 0.001) up-and down-regulated probes based on log ratio of gene expression during osteogenic differentiation at 6 h following the start of differentiation treatment, compared with time 0. We chose this time point to be able to temporally match it with the time of incubation of each compound within the CMap. Illumina probe identifiers were converted to Affymetrix probe identifiers, which are required for input into the CMap. After removal of duplicates, we ended up with 77 up-regulated genes and 66 down-regulated genes (Table S1) that we submitted simultaneously for our CMap query (build02; www.broadinstitute.org/cmap/). Each signature was queried against the CMap using the gene set enrichment analysis algorithm described by Lamb et al. (3) .
Flow Cytometric Analysis of Proliferation and Apoptosis. Apoptotic cells were determined based on staining with phycoerythrin (PE)-conjugated annexin V and 7-aminoactinomycin D (7AAD). Proliferating cells were identified as being Alexa 488-conjugated Ki67 + .
PrestoBlue Assay for Cell Survival Analysis. For analysis of cell survival we used the PrestoBlue cytotoxicity assay following the manufacturer's protocol.
Immunocytochemistry. Microtubules were visualized using mouse monoclonal anti-β-tubulin antibody. Focal adhesions were labeled with rabbit monoclonal ABfinity anti-Vinculin antibody. Quantitative morphometric analysis (length and number of focal adhesions per cell) was performed using ImageJ (NIH) as described previously (52) .
BMP Reporter Assay. We used a previously reported C2C12 cell line stably transfected with a reporter plasmid consisting of BMP-responsive elements from the Id1 promoter fused to a luciferase reporter gene (C2C12-BRE-Luc) to detect BMP activity (16, 17) following treatment with conditioned media from hMSCs exposed to parbendazole.
Statistics. The data provided here are based on at least two independent experiments performed in at least triplicate. Values displayed are mean ± SEM. Significance was calculated using either the Student's t test, oneway ANOVA with Tukey's or Dunn's post hoc test, or two-way ANOVA where appropriate, using GraphPad prism 6.0. P < 0.05 was considered significant. 
